Murine Fc gamma (Fcγ) receptor knockout in the NOG-EXL mouse provides a more accurate assessment of your antibody-based drug efficacy.

Nomenclature: NOD.Cg-Fcgr2b^tm1Ttk Fcer1g^tm1Rav Prkdc^scid Il2rg^tm1Sug Tg(SV40/HTLV-IL3,CSF2)10-7Jic/JicTac

• The FcResolv® NOG-EXL is a super immunodeficient NOG mouse that expresses human GM-CSF and IL-3 cytokines and has a further reduction in residual murine immune activity via ablation of mouse Fc gamma receptors (FcγRs) to reduce murine immune cell interactions with antibody-based drugs
• This model can be used in a similar fashion to the NOG-EXL mouse, including for xenograft and immune system humanization experiments
• Murine FcγRs can confound experiments in several ways, leading to false positive or negative results. Removing murine FcγRs provides improved accuracy for efficacy assessment of antibody-based therapies which include an Fc domain. 
  • Lacks all murine FcγRs, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.
• The NOG-EXL model was designed to express relatively low cytokine levels, which maintains the long-term stability of engraftment by preventing the exhaustion of the stem cell pool. This stability makes it a flexible platform for the generation of humanized mice.
  • Supports myeloid lineage engraftment through human IL-3 and GM-CSF cytokine expression
  • More efficient CD34+ human hematopoietic stem cell (HSC) engraftment
  • Higher levels of myeloid cell differentiation following human HSC engraftment
  • Low cytokine expression and successful long-term HSC engraftment
  • NOG-EXL mice are a superior host for acute myeloid leukemia (AML) patient-derived xenografts. 
• Research applications include the generation of humanized mouse models, oncology, infectious disease, and regenerative medicine.

Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Availability

Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3 weeks of age.

Origin

The FcResolv NOG-EXL mouse was developed by Taconic Biosciences. The Fcer1g^tm1Rav mutation was developed in the laboratory of J.V. Ravetch, Sloan-Kettering Institute. The Fcgr2b^tm1Ttk mutation was developed in the laboratory of T. Takai of Okayama University. These two mutations were backcrossed onto the CIEA NOG mouse^®, and the resulting FcResolv NOG mouse was crossed to the NOG-EXL strain to generate the FcResolv NOG-EXL strain. The mice are maintained by breeding females homozygous for the Fcer1g^tm1Rav, Fcgr2b^tm1Ttk, Prkdc^scid and Il2rg^tm1Sug mutant alleles with males that are homozygous for the Fcer1g^tm1Rav, Fcgr2b^tm1Ttk, Prkdc^scid alleles and hemizygous for the Il2rg^tm1Sug mutant allele and hGM-CSF/hIL-3 transgene or females homozygous for the Fcer1g^tm1Rav, Fcgr2b^tm1Ttk, Prkdc^scid and Il2rg^tm1Sug mutant alleles and hemizygous for the hGM-CSF/hIL-3 transgene by males homozygous for the Fcer1g^tm1Rav, Fcgr2b^tm1Ttk, Prkdc^scid alleles and hemizygous for the Il2rg^tm1Sug mutant allele.

FcResolv® refers to a United States trademark registration.